查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
支气管扩张剂市场,份额,规模,趋势,行业分析报告：按疾病,按给药途径,按药物类别,按作用方式,按地区,细分市场预测，2023-2032年
市场调查报告书
商品编码
1297955

支气管扩张剂市场,份额,规模,趋势,行业分析报告：按疾病,按给药途径,按药物类别,按作用方式,按地区,细分市场预测，2023-2032年

Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route Of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 116 Pages | 商品交期: 最快1-2个工作天内

价格

据Polaris Market Research最新研究显示，到2032年，全球支气管扩张剂市场规模预计将达到308.8亿美元。该报告提供了对当前市场动态的详细见解，并对未来市场增长进行了分析。

为了满足临床医生和肺科医生对使用新型支气管扩张剂组合（例如短效 BETA-2 激动剂和皮质类固醇）来立即缓解症状的日益增长的偏好和需求，这些将药物商业化的主要行业参与者预计将大幅增加支气管扩张剂的供应和采用。再加上全球人口老龄化，增加了患下呼吸道感染（LRTI）的风险，预计将促进市场增长。

例如，2023年1月，美国食品和药物管理局批准Airsupra用于治疗哮喘加重。这种创新的加压计量平台采用沙丁胺醇/布地奈德组合作为救援疗法，并辅以沙丁胺醇维持加强剂量。对速效支气管扩张剂的需求不断增长，推动了治疗主要呼吸道疾病的各种组合药物的批准，支持了市场增长。

最近呼吸医学的研究表明，儿童支气管收缩的病例有所增加，并且患者数量正在迅速增加。许多因素，包括遗传和不健康的饮食习惯，使儿童容易患上哮喘等长期呼吸道疾病。据推测，儿科呼吸药物的广泛使用以及世界各地各医疗机构的宣传活动和临床研究正在支持市场的增长。

例如，NCBI 2022 年 8 月发布的一项研究估计，美国儿童哮喘患病率为 8.4%，估计患病人数超过 600 万。此外，66.0%的儿童被发现患有严重哮喘，患病率很高。因此，儿科患者的增加以及现有患者库预计将推动对支气管扩张剂的需求，以用于严重病例的维持治疗和支气管缓解。

COVID-19 对支气管扩张剂市场的影响是积极的，因为它可以促进患有冠状病毒呼吸系统紧急情况的患者的正常呼吸。此外，这一时期肺炎等危及生命的疾病的高发导致支气管扩张剂等呼吸系统药物和支持性护理的大量涌入。再加上紧急方案和医疗保健指南的部署，推动了支气管扩张剂的使用，并由于呼吸道疾病入院人数增加，在大流行期间促进了市场增长。

支气管扩张剂市场报告亮点

  • 由于人们越来越意识到呼吸医学中支气管扩张剂治疗的益处以及慢性阻塞性肺病患者的高患病率，预计慢性阻塞性肺病细分市场在预测期内将以高复合年增长率增长。
  • 由于口服药物在减少支气管收缩发作方面的高成功率以及黄嘌呤衍生物在支持治疗中的使用越来越多，口服药物占据了最大的销售份额。
  • 由于BETA-肾上腺素能激动剂在呼吸医学领域的传统智慧以及与其他类别支气管扩张剂相比的有效治疗特性，预计在预测期内将占据较大的市场份额。
  • 由于空气污染引起的支气管炎和其他呼吸道疾病的发病率不断增加，预计北美在预测期内将出现显着增长。

目录

第 1 章 简介

第二章执行摘要

第三章研究方法论

第四章全球支气管扩张剂市场洞察

  • 支气管扩张剂 - 行业快照
  • 支气管扩张剂市场动态
    • 驱动因素和机遇
      • 哮喘和慢性阻塞性肺病的发病率增加
      • 新兴国家的各种增长机会
    • 限制和挑战
      • 与支气管扩张剂相关的副作用
  • PESTLE分析
  • 支气管扩张剂行业趋势
  • 价值链分析
  • COVID-19 感染的影响分析

5.全球支气管扩张剂市场（按疾病）

  • 主要发现
  • 介绍
  • 哮喘
  • 慢性阻塞性肺病
  • 其他

6. 全球支气管扩张剂市场（按给药途径）

  • 主要发现
  • 介绍
  • 可吸入的
  • 口服
  • 注射

7.全球支气管扩张剂市场，按药物类别

  • 主要发现
  • 介绍
  • BETA-肾上腺素能激动剂
  • 抗胆碱能药
  • 黄嘌呤衍生物
  • 磷酸二酯□抑製剂
  • 配合剂

8. 全球支气管扩张剂市场（按作用机制）

  • 主要发现
  • 介绍
  • 短效
  • 长效

第九章全球支气管扩张剂市场（按地区）

  • 主要发现
  • 介绍
    • 支气管扩张剂市场评估，地区，2019-2032
  • 支气管扩张剂市场-北美
    • 北美：支气管扩张剂市场，按疾病分类，2019-2032
    • 北美：支气管扩张剂市场，按作用机制，2019-2032
    • 北美：2019-2032 年按给药途径划分的支气管扩张剂市场
    • 北美：支气管扩张剂市场，按药物类别，2019-2032
    • 支气管扩张剂市场-美国
    • 支气管扩张剂市场-加拿大
  • 支气管扩张剂市场 - 欧洲
    • 欧洲：支气管扩张剂市场，按疾病分类，2019-2032
    • 欧洲：支气管扩张剂市场，按作用方式，2019-2032
    • 欧洲：2019-2032 年按给药途径划分的支气管扩张剂市场
    • 欧洲：支气管扩张剂市场，按药物类别，2019-2032
    • 支气管扩张剂市场 - 英国
    • 支气管扩张剂市场 - 法国
    • 支气管扩张剂市场-德国
    • 支气管扩张剂市场-意大利
    • 支气管扩张剂市场-西班牙
    • 支气管扩张剂市场 - 荷兰
    • 支气管扩张剂市场-俄罗斯
  • 支气管扩张剂市场 - 亚太地区
    • 亚太地区：支气管扩张剂市场，按疾病分类，2019-2032
    • 亚太地区：支气管扩张剂市场，按作用机制，2019-2032
    • 亚太地区：按给药途径划分的支气管扩张剂市场，2019-2032 年
    • 亚太地区：支气管扩张剂市场，按药物类别，2019-2032
    • 支气管扩张剂市场-中国
    • 支气管扩张剂市场-印度
    • 支气管扩张剂市场-日本
    • 支气管扩张剂市场-马来西亚
    • 支气管扩张剂市场-印度尼西亚
    • 支气管扩张剂市场-韩国
  • 支气管扩张剂市场-中东和非洲
    • 中东和非洲：支气管扩张剂市场，按疾病分类，2019-2032
    • 中东和非洲：支气管扩张剂市场，按作用机制，2019-2032
    • 中东和非洲：2019-2032 年按给药途径划分的支气管扩张剂市场
    • 中东和非洲：支气管扩张剂市场，按药物类别，2019-2032
    • 支气管扩张剂市场-沙特阿拉伯
    • 支气管扩张剂市场-南非
    • 支气管扩张剂市场-以色列
    • 支气管扩张剂市场-阿拉伯联合酋长国
  • 支气管扩张剂市场 - 拉丁美洲
    • 拉丁美洲：支气管扩张剂市场，按疾病分类，2019-2032 年
    • 拉丁美洲：支气管扩张剂市场，按作用机制，2019-2032
    • 拉丁美洲：按给药途径划分的支气管扩张剂市场，2019-2032 年
    • 拉丁美洲：支气管扩张剂市场，按药物类别，2019-2032
    • 支气管扩张剂市场-墨西哥
    • 支气管扩张剂市场-巴西
    • 支气管扩张剂市场-阿根廷

第10章 竞争格局

  • 扩张和收购分析
    • 扩张
    • 获得
  • 联盟/合作/协议/披露

第十一章公司简介

  • GSK
  • AstraZeneca
  • Teva Pharmaceutical
  • Cipla Inc
  • Mylan
  • Merck
  • Novartis
  • Boehringer Ingelheim
  • Sun Pharmaceutical Industries
  • Glenmark Pharmaceuticals Limited
Product Code: PM3204

The global bronchodilators market size is expected to reach USD 30.88 billion by 2032, according to a new study by Polaris Market Research. The report "Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing preference of clinicians and respiratory experts on utilizing novel bronchodilator combinations such as short-acting beta 2 agonists along with corticosteroids for immediate relief along with key industry players commercializing these drugs to cater the rising demand is estimated to surge availability and adoption of bronchodilators. This coupled with rise in ageing population globally at a higher risk of developing Lower Respiratory Tract Infections (LRTI) are anticipated to augment the growth of the market.

For instance, in January 2023, the U.S. Food and Drug administration approved Airsupra for the therapy of Asthma with exacerbations. The innovative pressurized metering platform delivers the combination albuterol/budesonide as a rescue therapy, supplemented by maintenance of additional albuterol dose. The increasing need of quick acting bronchodilators is promoting key players in gaining approvals for various combinations to cater major respiratory disorders thereby supporting the growth of the market.

Recent studies in respiratory medicine have shown increasing occurrence of bronchoconstriction cases in children which is growing rapidly among the patient pool. Various factors such as genetics, unhealthy food habits, among others are making of pediatrics susceptible to long term respiratory conditions such as Asthma. This along with awareness campaigns and clinical research by various healthcare bodies around the globe, promoting pediatric respiratory medication is estimated to support the growth of the market.

For instance, a research study published by the NCBI, in August 2022, the prevalence of children suffering from Asthma in the U.S. was estimated to be 8.4%, estimated over 6 million patient population. Moreover, 66.0% of children were found to be suffering from severe cases of Asthma with a high morbidity rate. Therefore, the increasing presence of pediatric patients along with the existing patient pool is anticipated to drive the demand for bronchodilators owing to maintenance therapy and bronchial alleviation in cases of severity.

The impact of COVID-19 on the bronchodilator market was favorable due facilitation of normal breathing for patients affected by the corona virus induced respiratory emergencies. Moreover, high incidence rates of life threatening diseases such as pneumonia during the period demanded an inflow of respiratory medications and supportive therapies such as bronchodilation. This coupled with deployment of emergency protocols and healthcare guidelines, increasing hospital admissions with respiratory complaints promoted the use of bronchodilators thereby bolstering the growth of the market during the pandemic.

Bronchodilators Market Report Highlights

  • COPD segment is anticipated to grow at a high CAGR over the forecast period owing to rising awareness of bronchodilation therapy benefits in respiratory medicine along with high prevalence of COPD among patient population.
  • Oral accounted for largest revenue share which is accelerated by the higher success rates of oral drugs in reducing bronconstriction episodes along increasing applications of Xanthine derivatives in supportive therapies.
  • Beta-Adrenergics is expected to hold the significant market share over the forecast period due to its conventional wisdom in respiratory medicine along with effective treatment profile as compared to other classes of bronchodilators.
  • North America is expected to grow prominently over the projected period owing to increasing incidence of bronchitis and other respiratory disorders triggered due to air pollution.
  • The global players in the market include GSK, AstraZeneca, Teva Pharmaceutical, Cipla Inc., Mylan, Merck, Novartis, Boehringer Ingelheim, Sun Pharmaceutical, Glenmark Pharmaceuticals.

Polaris Market Research has segmented the bronchodilators market report based by disease, by route of administration, by drug class, by mode of action and region:

Bronchodilators, Disease Outlook (Revenue - USD Billion, 2019 - 2032)

  • Asthma
  • COPD
  • Others

Bronchodilators, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Inhalable
  • Oral
  • Injection

Bronchodilators, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Beta-Adrenergics
  • Anticholinergics
  • Xanthine Derivatives
  • Phosphodiesterase Inhibitors
  • Combination Drugs

Bronchodilators, Mode of Action Outlook (Revenue - USD Billion, 2019 - 2032)

  • Short Acting
  • Long Acting

Bronchodilators, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Bronchodilators Market Insights

  • 4.1. Bronchodilators - Industry Snapshot
  • 4.2. Bronchodilators Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rise in incidence of asthma and COPD
      • 4.2.1.2. Various growth opportunities in emerging economies
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Side effects associated with bronchodilators
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Bronchodilators Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Bronchodilators Market, by Disease

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • 5.3. Asthma
    • 5.3.1. Global Bronchodilators Market, by Asthma, by Region, 2019-2032 (USD Billion)
  • 5.4. COPD
    • 5.4.1. Global Bronchodilators Market, by COPD, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Bronchodilators Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Bronchodilators Market, by Route Of Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • 6.3. Inhalable
    • 6.3.1. Global Bronchodilators Market, by Inhalable, by Region, 2019-2032 (USD Billion)
  • 6.4. Oral
    • 6.4.1. Global Bronchodilators Market, by Oral, by Region, 2019-2032 (USD Billion)
  • 6.5. Injection
    • 6.5.1. Global Bronchodilators Market, by Injection, by Region, 2019-2032 (USD Billion)

7. Global Bronchodilators Market, by Drug Class

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 7.3. Beta-Adrenergics
    • 7.3.1. Global Bronchodilators Market, by Beta-Adrenergics, by Region, 2019-2032 (USD Billion)
  • 7.4. Anticholinergics
    • 7.4.1. Global Bronchodilators Market, by Anticholinergics, by Region, 2019-2032 (USD Billion)
  • 7.5. Xanthine Derivatives
    • 7.5.1. Global Bronchodilators Market, by Xanthine Derivatives, by Region, 2019-2032 (USD Billion)
  • 7.6. Phosphodiesterase Inhibitors
    • 7.6.1. Global Bronchodilators Market, by Phosphodiesterase Inhibitors, by Region, 2019-2032 (USD Billion)
  • 7.7. Combination Drugs
    • 7.7.1. Global Bronchodilators Market, by Combination Drugs, by Region, 2019-2032 (USD Billion)

8. Global Bronchodilators Market, by Mode of Action

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • 8.3. Short Acting
    • 8.3.1. Global Bronchodilators Market, by Short Acting, by Region, 2019-2032 (USD Billion)
  • 8.4. Long Acting
    • 8.4.1. Global Bronchodilators Market, by Long Acting, by Region, 2019-2032 (USD Billion)

9. Global Bronchodilators Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Bronchodilators Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 9.3. Bronchodilators Market - North America
    • 9.3.1. North America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.3.2. North America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.3.3. North America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.3.4. North America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.5. Bronchodilators Market - U.S.
      • 9.3.5.1. U.S.: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.3.5.2. U.S.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.3.5.3. U.S.: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.3.5.4. U.S.: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.3.6. Bronchodilators Market - Canada
      • 9.3.6.1. Canada: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.3.6.2. Canada: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.3.6.3. Canada: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.3.6.4. Canada: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.4. Bronchodilators Market - Europe
    • 9.4.1. Europe: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.4.2. Europe: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.4.3. Europe: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.4.4. Europe: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.5. Bronchodilators Market - UK
      • 9.4.5.1. UK: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.5.2. UK: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.5.3. UK: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.5.4. UK: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.6. Bronchodilators Market - France
      • 9.4.6.1. France: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.6.2. France: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.6.3. France: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.6.4. France: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.7. Bronchodilators Market - Germany
      • 9.4.7.1. Germany: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.7.2. Germany: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.7.3. Germany: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.7.4. Germany: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.8. Bronchodilators Market - Italy
      • 9.4.8.1. Italy: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.8.2. Italy: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.8.3. Italy: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.8.4. Italy: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.9. Bronchodilators Market - Spain
      • 9.4.9.1. Spain: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.9.2. Spain: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.9.3. Spain: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.9.4. Spain: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.10. Bronchodilators Market - Netherlands
      • 9.4.10.1. Netherlands: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.10.2. Netherlands: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.10.3. Netherlands: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.10.4. Netherlands: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.4.11. Bronchodilators Market - Russia
      • 9.4.11.1. Russia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.4.11.2. Russia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.4.11.3. Russia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.4.11.4. Russia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.5. Bronchodilators Market - Asia Pacific
    • 9.5.1. Asia Pacific: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.5.2. Asia Pacific: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.5.3. Asia Pacific: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.5.4. Asia Pacific: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.5. Bronchodilators Market - China
      • 9.5.5.1. China: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.5.2. China.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.5.3. China: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.5.4. China: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.6. Bronchodilators Market - India
      • 9.5.6.1. India: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.6.2. India.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.6.3. India: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.6.4. India: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.7. Bronchodilators Market - Japan
      • 9.5.7.1. Japan: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.7.2. Japan.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.7.3. Japan: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.7.4. Japan: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.8. Bronchodilators Market - Malaysia
      • 9.5.8.1. Malaysia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.8.2. Malaysia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.8.3. Malaysia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.8.4. Malaysia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.9. Bronchodilators Market - Indonesia
      • 9.5.9.1. Indonesia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.9.2. Indonesia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.9.3. Indonesia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.9.4. Indonesia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.5.10. Bronchodilators Market - South Korea
      • 9.5.10.1. South Korea: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.5.10.2. South Korea.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.5.10.3. South Korea: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.5.10.4. South Korea: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.6. Bronchodilators Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.6.2. Middle East & Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.6.3. Middle East & Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.6.4. Middle East & Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.5. Bronchodilators Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.6. Bronchodilators Market - South Africa
      • 9.6.6.1. South Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.6.6.2. South Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.6.6.3. South Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.6.6.4. South Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.7. Bronchodilators Market - Israel
      • 9.6.7.1. Israel: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.6.7.2. Israel: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.6.7.3. Israel: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.6.7.4. Israel: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.6.8. Bronchodilators Market - UAE
      • 9.6.8.1. UAE: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.6.8.2. UAE: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.6.8.3. UAE: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.6.8.4. UAE: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • 9.7. Bronchodilators Market - Latin America
    • 9.7.1. Latin America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
    • 9.7.2. Latin America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
    • 9.7.3. Latin America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
    • 9.7.4. Latin America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.5. Bronchodilators Market - Mexico
      • 9.7.5.1. Mexico: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.7.5.2. Mexico: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.7.5.3. Mexico: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.7.5.4. Mexico: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.6. Bronchodilators Market - Brazil
      • 9.7.6.1. Brazil: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.7.6.2. Brazil: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.7.6.3. Brazil: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.7.6.4. Brazil: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
    • 9.7.7. Bronchodilators Market - Argentina
      • 9.7.7.1. Argentina: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
      • 9.7.7.2. Argentina: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
      • 9.7.7.3. Argentina: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
      • 9.7.7.4. Argentina: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. GSK
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. AstraZeneca
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Teva Pharmaceutical
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Cipla Inc
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Mylan
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Merck
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Novartis
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Boehringer Ingelheim
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Sun Pharmaceutical Industries
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Glenmark Pharmaceuticals Limited
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development

List of Tables

  • Table 1 Global Bronchodilators Market, by Disease, by Region, 2019-2032 (USD Billion)
  • Table 2 Global Bronchodilators Market, by Route Of Administration, by Region, 2019-2032 (USD Billion)
  • Table 3 Global Bronchodilators Market, by Drug Class, by Region, 2019-2032 (USD Billion)
  • Table 4 Global Bronchodilators Market, by Mode of Action, by Region, 2019-2032 (USD Billion)
  • Table 5 Bronchodilators Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 6 North America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 7 North America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 8 North America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 North America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 10 U.S.: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 11 U.S.: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 12 U.S.: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 13 U.S.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 14 Canada: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 15 Canada: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 16 Canada: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 17 Canada: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 18 Europe: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 19 Europe: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 20 Europe: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 Europe: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 22 Germany: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 23 Germany: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 24 Germany: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 25 Germany: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 26 France: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 27 France: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 28 France: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 29 France: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 30 UK: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 31 UK: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 32 UK: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 UK: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 34 Italy: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 35 Italy: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 36 Italy: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 37 Italy: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 38 Netherlands: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 39 Netherlands: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 40 Netherlands: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 41 Netherlands: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 42 Spain: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 43 Spain: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 44 Spain: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 Spain: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 46 Russia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 47 Russia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 48 Russia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 49 Russia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 50 Asia Pacific: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 51 Asia Pacific: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 52 Asia Pacific: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 53 Asia Pacific: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 54 China: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 55 China: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 56 China: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 China: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 58 Japan: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 59 Japan: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 60 Japan: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 61 Japan: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 62 India: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 63 India: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 64 India: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 65 India: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 66 Indonesia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 67 Indonesia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 68 Indonesia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Indonesia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 70 Malaysia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 71 Malaysia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 72 Malaysia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 73 Malaysia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 74 South Korea: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 75 South Korea: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 76 South Korea: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 77 South Korea: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 78 Latin America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 79 Latin America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 80 Latin America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Latin America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 82 Brazil: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 83 Brazil: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 84 Brazil: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 85 Brazil: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 86 Mexico: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 87 Mexico: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 88 Mexico: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 89 Mexico: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 90 Argentina: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 91 Argentina: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 92 Argentina: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 93 Argentina: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 94 Middle East & Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 95 Middle East & Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 96 Middle East & Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 97 Middle East & Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 98 UAE: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 99 UAE: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 100 UAE: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 101 UAE: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 102 Saudi Arabia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 103 Saudi Arabia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 104 Saudi Arabia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 105 Saudi Arabia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 106 South Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 107 South Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 108 South Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 109 South Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
  • Table 110 Israel: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
  • Table 111 Israel: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
  • Table 112 Israel: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 113 Israel: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Bronchodilators Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Mode of Action
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Disease
  • Figure 7. Global Bronchodilators Market, by Disease, 2021 & 2030 (USD Billion)
  • Figure 8. Market by Mode of Action
  • Figure 9. Global Bronchodilators Market, by Mode of Action, 2021 & 2030 (USD Billion)
  • Figure 10. Market by Route Of Administration
  • Figure 11. Global Bronchodilators Market, by Route Of Administration, 2021 & 2030 (USD Billion)
  • Figure 12. Market by Drug Class
  • Figure 13. Global Bronchodilators Market, by Drug Class, 2021 & 2030 (USD Billion)